Applying data from clinical trials is intrinsically problematic because the benefits of an intervention are presented as group averages and do not describe how an individual patient will respond. Canney et al.
conducted a secondary analysis of Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) study, a trial that evaluated glucocorticoids in IgA nephropathy (IgAN). In this study, the average absolute risk reduction (ARR) for the composite outcome of a 40% decline in estimated glomerular filtration rate (eGFR), kidney failure, or death was 16%.
Kidney International published a clinical update in Research Highlights on 01 Apr 2026.
The item focuses on in this issue.
Review the original article for the full source wording and details.